A 35-year-old woman from Mumbai presents with gross hematuria, proteinuria (2.5 g/day), and hypertension (BP 160/100 mmHg) for 3 weeks. Serum creatinine is 2.8 mg/dL (baseline 0.9 mg/dL). Urine shows dysmorphic RBCs, RBC casts, and WBC casts. Serologies: ANA positive (1:320, homogeneous), anti-dsDNA positive (high titre), anti-C1q positive. C3 and C4 are low. Chest X-ray shows no pulmonary hemorrhage. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis This patient has **lupus nephritis (LN)** with evidence of active proliferative disease: - **Serological markers:** ANA+, anti-dsDNA+, anti-C1q+, low C3/C4 (active lupus) - **Clinical features:** Acute nephritic syndrome (dysmorphic RBCs, RBC casts, WBC casts) - **Renal dysfunction:** Creatinine doubled (0.9 → 2.8 mg/dL) — indicates active glomerulonephritis - **Proteinuria:** 2.5 g/day (nephritic range) ## Diagnostic Confirmation & Staging **Key Point:** Kidney biopsy is **mandatory** in suspected lupus nephritis to: 1. Confirm diagnosis (electron microscopy shows subendothelial/subepithelial immune deposits) 2. Determine **ISN/RPS class** (I–VI) — guides treatment intensity 3. Assess activity and chronicity indices ### Expected Biopsy Findings in This Case Likely **Class III (focal proliferative) or Class IV (diffuse proliferative)** LN, given: - Active serologies (anti-dsDNA, low C3/C4) - Dysmorphic RBCs and casts - Significant proteinuria and renal dysfunction ## Induction Therapy Protocol **High-Yield:** Standard induction therapy for proliferative LN (Class III–IV): | Component | Regimen | Duration | |-----------|---------|----------| | **Corticosteroids** | IV methylprednisolone 500 mg–1 g daily × 3 days, then oral prednisolone 0.5–1 mg/kg/day | 6–12 weeks, then taper | | **Immunosuppression** | Cyclophosphamide (Euro-Lupus: 500 mg fixed dose × 6 pulses) OR Mycophenolate mofetil (1–3 g/day) | 6 months | | **Supportive** | ACE inhibitor/ARB, antihypertensives, salt restriction | Ongoing | **Clinical Pearl:** Euro-Lupus regimen (fixed 500 mg cyclophosphamide × 6 pulses) is preferred in many centers because it achieves remission rates similar to high-dose protocols with **lower cumulative toxicity** and reduced infertility risk. ## Why Biopsy Must Precede Treatment **Mnemonic: BIOPSY FIRST** — **B**efore **I**nduction, **O**btain **P**athology to **S**tage **Y**our lupus - Biopsy determines **ISN/RPS class** → treatment intensity - Class I–II (minimal/mesangial) → may respond to corticosteroids alone - Class III–IV (proliferative) → require combination induction therapy - Class V (membranous) → different treatment approach (calcineurin inhibitors or MMF) Without biopsy, you risk **under-treating** proliferative disease (leading to renal failure) or **over-treating** minimal disease (unnecessary toxicity).